Carl Brooks

Discovery of GSK2193874: An Orally Active, Potent, and Selective Blocker of Transient Receptor Potential Vanilloid 4

Mui Cheung, Weike Bao, David J. Behm et al. · ACS Medicinal Chemistry Letters · 2017 · 94 citations · Full text

Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4)

Carl Brooks, Linda S. Barton, David J. Behm et al. · ACS Medicinal Chemistry Letters · 2019 · 51 citations · Full text

Identification of a sulfonamide series of CCR2 antagonists

Simon Peace, Joanne Philp, Carl Brooks et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 35 citations · Full text

Medicine, Sulfonamide Series, Mechanism Of Action +4

Design and Optimization of Sulfone Pyrrolidine Sulfonamide Antagonists of Transient Receptor Potential Vanilloid-4 with in Vivo Activity in a Pulmonary Edema Model

Joseph E. Pero, Jay M. Matthews, David J. Behm et al. · Journal of Medicinal Chemistry · 2018 · 34 citations · Full text

Discovery of Pyrrolidine Sulfonamides as Selective and Orally Bioavailable Antagonists of Transient Receptor Potential Vanilloid-4 (TRPV4)

Edward J. Brnardic, Guosen Ye, Carl Brooks et al. · Journal of Medicinal Chemistry · 2018 · 27 citations · Full text